计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| G107681-20mg |
20mg |
现货 ![]() |
| |
| G107681-50mg |
50mg |
现货 ![]() |
| |
| G107681-100mg |
100mg |
期货 ![]() |
|
| 别名 | 20 (S)-人参皂苷-Rg3 | (3β,12β,20S)-12,20-二羟基达玛-24-烯-3-基2-O-β-D-吡喃葡萄糖基-β-D-吡喃葡萄糖苷 | (3β, 12β)-12,20-二羟基 dmar-24-烯-3-基 2- O -β- D -吡喃葡萄糖基-β- D -吡喃葡萄糖苷 |
|---|---|
| 英文别名 | 20(S)-Ginsenoside Rg3 | (3β,12β)-12,20-Dihydroxydammar-24-en-3-yl 2-O-β-D-glucopyranosyl-β-D-glucopyranoside |
| 规格或纯度 | Moligand™, 分析标准品, ≥98% |
| 英文名称 | Ginsenoside Rg3 |
| 生化机理 | 人参皂苷 Rg3 是一种从人参中分离出来的天然产品。与其他人参皂甙类似,它具有保护心脏的作用。人参皂苷 Rg3 通过与通道孔入口的相互作用,增强心脏、hERG(IKr)和 KCNQ(Iks)通道电流。人参皂苷 Rg3 还能通过调节 p44/42 MAPK 激活 β 细胞凋亡,抑制棕榈酸酯诱导的 MIN6N8 小鼠胰岛素瘤。人参皂苷 Rg3 能提高转录因子 Nrf2 的水平,诱导多药耐药性相关蛋白(Mrp)1 和 Mrp3 的 mRNA 水平。Rg3 可降低小胶质细胞对全身性 LPS 处理的反应,从而调节神经炎症。它能激活 HepG2 细胞中的 AMPK,减少脂质积累,从而降低由血脂异常引起的心血管疾病的风险。 |
| 储存温度 | 2-8°C储存,避光 |
| 运输条件 | 冰袋运输 |
| 作用类型 | 激活剂 |
| 作用机制 | K 激活程序 v11.1 |
| 纯度 | ≥98% |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| 分子类型 | 小分子 |
|---|---|
| IIUPAC Name | (2S,3R,4S,5S,6R)-2-[(2R,3R,4S,5S,6R)-4,5-dihydroxy-2-[[(3S,5R,8R,9R,10R,12R,13R,14R,17S)-12-hydroxy-17-[(2S)-2-hydroxy-6-methylhept-5-en-2-yl]-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]-6-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol |
| INCHI | 1S/C42H72O13/c1-21(2)10-9-14-42(8,51)22-11-16-41(7)29(22)23(45)18-27-39(5)15-13-28(38(3,4)26(39)12-17-40(27,41)6)54-37-35(33(49)31(47)25(20-44)53-37)55-36-34(50)32(48)30(46)24(19-43)52-36/h10,22-37,43-51H,9,11-20H2,1-8H3/t22-,23+,24+,25+,26-,27+,28-,29-,30+,31+,32-,33-,34+,35+,36-,37-,39-,40+,41+,42-/m0/s1 |
| InChi Key | RWXIFXNRCLMQCD-JBVRGBGGSA-N |
| Smiles | CC(=CCCC(C)(C1CCC2(C1C(CC3C2(CCC4C3(CCC(C4(C)C)OC5C(C(C(C(O5)CO)O)O)OC6C(C(C(C(O6)CO)O)O)O)C)C)O)C)O)C |
| Isomeric SMILES | CC(=CCC[C@@](C)([C@H]1CC[C@@]2([C@@H]1[C@@H](C[C@H]3[C@]2(CC[C@@H]4[C@@]3(CC[C@@H](C4(C)C)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)C)C)O)C)O)C |
| 关联CAS | 38243-03-7 |
| 分子量 | 785.01 |
| Reaxy-Rn | 27844255 |
| Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=27844255&ln= |
| 密度 | 1.3 |
|---|---|
| 敏感性 | 对湿度敏感,对光敏感,对热敏感 |
| 熔点 | 175-177oC |
| 分子量 | 785.000 g/mol |
| XLogP3 | 4.000 |
| 氢键供体数Hydrogen Bond Donor Count | 9 |
| 氢键受体数Hydrogen Bond Acceptor Count | 13 |
| 可旋转键计数Rotatable Bond Count | 10 |
| 精确质量Exact Mass | 784.497 Da |
| 单同位素质量Monoisotopic Mass | 784.497 Da |
| 拓扑极表面积Topological Polar Surface Area | 219.000 Ų |
| 重原子数Heavy Atom Count | 55 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 1370.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 20 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 象形图 | GHS07 |
|---|---|
| 信号词 | Warning |
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
| 批号(Lot Number) | 证书类型 | 货号 |
|---|---|---|
| 分析证书 | G107681 | |
| 分析证书 | G107681 | |
| 分析证书 | G107681 | |
| 分析证书 | G107681 | |
| 分析证书 | G107681 | |
| 分析证书 | G107681 | |
| 分析证书 | G107681 | |
| 分析证书 | G107681 | |
| 分析证书 | G107681 | |
| 分析证书 | G107681 | |
| 分析证书 | G107681 | |
| 分析证书 | G107681 | |
| 分析证书 | G107681 | |
| 分析证书 | G107681 | |
| 分析证书 | G107681 | |
| 分析证书 | G107681 | |
| 分析证书 | G107681 | |
| 分析证书 | G107681 | |
| 分析证书 | G107681 | |
| 分析证书 | G107681 | |
| 分析证书 | G107681 | |
| 分析证书 | G107681 | |
| 分析证书 | G107681 |
| 1. Zeng Xiangfeng, Liu Shengyao, Yang Hua, Jia Menglei, Liu Wei, Zhu Wenting. (2023) Synergistic anti-tumour activity of ginsenoside Rg3 and doxorubicin on proliferation, metastasis and angiogenesis in osteosarcoma by modulating mTOR/HIF-1α/VEGF and EMT signalling pathways. JOURNAL OF PHARMACY AND PHARMACOLOGY, [PMID:37498992] [10.1093/jpp/rgad070] |
| 2. Ren Rongfan, Li Hongli, Jiang Qing, Wang Xing, Chen David Da Yong. (2023) Characterization of ginsenoside structural isomers from mixtures using in situ methylation with direct analysis in real-time ionization tandem mass spectrometry. ANALYTICAL AND BIOANALYTICAL CHEMISTRY, 415 (5): (887-897). [PMID:36571591] [10.1007/s00216-022-04482-w] |
| 3. Tianhua Liu, Ling Zuo, Dongqing Guo, Xinlou Chai, Jie Xu, Zhaorui Cui, Zhiyi Wang, Chunying Hou. (2019) Ginsenoside Rg3 regulates DNA damage in non-small cell lung cancer cells by activating VRK1/P53BP1 pathway. BIOMEDICINE & PHARMACOTHERAPY, 120 (109483). [PMID:31629252] [10.1016/j.biopha.2019.109483] |
| 4. Nan Zhao, Mengchun Cheng, Shuai Huang, Dan Liu, Qiang Zhao, Yunpeng Bai, Xiaozhe Zhang. (2019) Various Multicharged Anions of Ginsenosides in Negative Electrospray Ionization with QTOF High-Resolution Mass Spectrometry. JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY, 30 (3): (403–418). [PMID:30644055] [10.1007/s13361-018-2089-5] |
| 5. Lu Jianrao, Yi Yang, Pan Ronghua, Zhang Chuanfu, Han Haiyan, Chen Jie, Liu Wenrui. (2018) Berberine protects HK-2 cells from hypoxia/reoxygenation induced apoptosis via inhibiting SPHK1 expression. Journal of Natural Medicines, 72 (2): (390-398). [PMID:29260413] [10.1007/s11418-017-1152-z] |
| 6. Chong Zhong, Yong-Fa Zhang, Jun-Hai Huang, Zi-Yu Wang, Qiu-Yuan Chen, Li-Tian Su, Zhen-Tao Liu, Cheng-Ming Xiong, Zhi Tao, Rong-Ping Guo. (2017) The Chinese medicine, Jianpi Huayu Decoction, inhibits the epithelial mesenchymal transition via the regulation of the Smad3/Smad7 cascade. American Journal of Translational Research, 9 (6): ( 2694–2711). [PMID:28670362] |
| 7. Xiaonan Zhang, Kang Chen, Bo Wei, Xingwang Liu, Zeming Lei, Xizhuang Bai. (2016) Ginsenosides Rg3 attenuates glucocorticoid-induced osteoporosis through regulating BMP-2/BMPR1A/Runx2 signaling pathway. CHEMICO-BIOLOGICAL INTERACTIONS, 256 (188). [PMID:27387537] [10.1016/j.cbi.2016.07.003] |